ICU Medical : Q3 2024 ICU Medical Earnings Call Presentation

ICUI

ICU Medical, Inc

Q3 2024 Conference Call

Presentation

November 12, 2024

Disclosures

2

2023-2024 Adjusted Revenue

In $ millions, unaudited

3

Together Announce

Joint Venture to Bolster IV Solutions Manufacturing and Innovation in the North American Market

Nov. 12, 2024

Otsuka Group Profile

Founded in 1921, Otsuka is a leading manufacturer of IV solutions outside North America and pharmaceutical products globally, aiming to create innovative products that meet a variety of clinical needs.

Otsuka Holdings

CY2023 Financial Overview

Market Capitalization (Nov. 2024)

~$33 Billion

Revenues

$14.2 Billion

Otsuka

(OPF)

Otsuka

(OPC)

Pharmaceutical

Pharmaceutical

Factory, Inc.

Co., Ltd.

Core Pharmaceutical and Nutraceutical Businesses

From diagnosis and treatment of disease to

maintaining and improving daily life

Otsuka Foods

Otsuka

Medical

Devices

Otsuka Chemical

Taiho

Pharmaceutical

Otsuka Warehouse

Business Profit1

$2.2 Billion

North American Revenues

~43%

Capital Expenditures

$1.5 Billion

Cash and Cash Equivalents

$3.6 Billion

Interest-bearing Debt2

$1.5 Billion

Figures are calculated at ¥141.82 = US$1 (closing rate at the end of the period)

1 Business profit = Revenue − Cost of sales − SG&A expenses + Share of profit of associates− R&D expenses 2 Interest-bearing debt is the total of bonds and borrowings, and lease liabilities

Otsuka Track Record of Innovation and Full PVC-Free Portfolio

Admixture

Parenteral Nutrition: TPN

Parenteral Nutrition: PPN

Premix, Ready-to-Use

The world's first premix IV antibiotic kit that is easy to use, helps minimize microbial contamination risk, reduces workload, and saves time

Why Otsuka

Transaction

Highlights

ICU Medical was deeply attracted to Otsuka for a set of core reasons:

Key economic terms of the Joint Venture:

JV Becomes Part of Manufacturing Network with Scale and Redundancy

Creates one of the largest IV solutions manufacturing networks on the planet

~1.4B annual units of combined production

17 combined global manufacturing sites

Significant CapEx investment to support IV Solutions growth

Otsuka: A Strong, Like-Minded Partner with Valuable Experience

Financial Strength

Cultural Mindset

"Creating new products

for better health worldwide."

These words embody Otsuka's dedication to:

Otsuka is dedicated to cultivating a dynamic corporate culture and workplaces that reflect their vision as a healthcare company, finding ways to live in harmony with local communities and the natural environment while contributing to richer and healthier lives.

U.S. Partnership Experience

Otsuka & Bristol-Myers Squibb Co-developand co-commercializethe antipsychotic drug ABILIFY®

(1999-2015)

Otsuka & Lundbeck Co-developand co-commercializeseveral psychiatric and neurological drugs including ABILIFY MAINTENA®, ABILIFY ASIMTUFII® and REXULTI®

(2011-Present)

Transaction Structure Key Items

Joint Venture

Setup

Benefits to

ICU Medical Shareholders

Pro Forma

Financial Impact

Disclaimer

ICU Medical Inc. published this content on November 13, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 13, 2024 at 04:05:06.301.